Skip to search formSkip to main contentSkip to account menu

E 7070

Known as: E-7070, E7070 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Sulfonamide Anti-Infective Agents

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
Clinical complete long-term remission of a patient with metastatic malignant melanoma under therapy with indisulam (E7070).
The objective of this study is to report on long-term survival of a patient with metastatic melanoma treated with indisulam… 
2006
2006
CDK inhibitors in 3D: Problems with the drugs, their development plans or their linkage to disease?
A battery system for supplying electric energy from a primary battery or a secondary battery to a load. This system includes a… 
2004
2004
Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography…
E7070 (indisulam) is a novel anticancer drug currently undergoing clinical investigation. We present a sensitive and specific… 
2003
2003
New Analogues of the Anticancer E7070: Synthesis and Pharmacology
Cell cycle control in the G1 phase has attracted considerable attention in recent cancer research, because many of the important… 
Review
2002
Review
2002
E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer.
Cell cycle regulation and cell growth are interesting targets in the search for new antitumor agents as these processes are… 
2002
2002
An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients
E7070 is a novel sulfonamide anticancer agent that arrests the G1/S phase of the cell cycle. Preclinical and phase I studies have… 
2002
2002
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).
AIMS E7070 is a novel, sulphonamide anticancer agent currently under clinical development for the treatment of solid tumours. The… 
2002
2002
Synthesis and biological evaluation of N-(7-indolyl)-3-pyridinesulfonamide derivatives as potent antitumor agents.
2002
2002
Population pharmacokinetics and pharmacokinetic‐pharmacodynamic relationships of the novel anticancer agent E7070 in four phase I studies
E7070 is a novel chloroindolyl sulphonamide being developed as an anti-cancer agent for the treatment of solid tumours. E7070… 
2001
2001
Anticancer agent E7070 inhibits amino acid and uracil transport in fission yeast.
E7070 is a novel sulfonamide anticancer agent that inhibits cell cycle progression in G1 in mammalian cells, but its action… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)